title: Laboratory Medicine in the Clinical Decision Support for Treatment of Hypercholesterolemia: Pharmacogenetics of Statins.
abstract: Statin responsiveness is an area of great research interest given the success of the drug class in the treatment of hypercholesterolemia and in primary and secondary prevention of cardiovascular disease. Interrogation of the patient's genome for gene variants will eventually guide anti-hyperlipidemic intervention. In this review, we discuss methodological approaches to discover genetic markers predictive of class-wide and drug-specific statin efficacy and safety. Notable pharmacogenetic findings are summarized from hypothesis-free genome wide and hypothesis-led candidate gene association studies. Physiogenomic models and clinical decision support systems will be required for DNA-guided statin therapy to reach practical use in medicine.
authors: Genomas Inc., 67 Jefferson Street, Hartford, CT 06106, USA. Electronic address: g.ruano@genomas.net.
authors: Gualberto
authors: G
authors: Ruaño
authors: Sanofi Genzyme, 500 Kendall Street, Cambridge, MA 02142, USA.
authors: Richard
authors: R
authors: Seip
authors: Cyclica Inc., 10 Jonathan Street, Belmont, MA 02478, USA.
authors: Andreas
authors: A
authors: Windemuth
authors: Department of Laboratory Medicine, San Francisco General Hosptial, 1001 Potrero Avenue, San Francisco, CA 94110, USA.
authors: Alan H B
authors: AH
authors: Wu
authors: Division of Cardiology, Hartford Hospital, 80 Seymour Street, Hartford, CT 06106, USA.
authors: Paul D
authors: PD
authors: Thompson
mesh_terms: D002318:Cardiovascular Diseases / Q000517:prevention & control*; D020000:Decision Support Systems, Clinical; D005838:Genotype; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000188:drug therapy* / Q000235:genetics*; D007753:Laboratories; D000071184:Pharmacogenomic Variants; D010641:Phenotype; D011322:Primary Prevention; D055502:Secondary Prevention
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: Coenzyme Q(10); Lipid metabolism; Myalgia; Myopathy; PCSK9 inhibitors; Pharmacogenetics; Physiogenomics; Statins